Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial Comparing Efficacy and Safety of Initial Triple Therapy Including Parenteral Treprostinil to Initial Double Oral Therapy in Pulmonary Arterial Hypertension (PAH) Group I Patients (TripleTRE)

NCT06317805 is registered in ClinicalTrials.gov with AOP Orphan Pharmaceuticals AG as lead sponsor.

NCT NCT06317805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06317805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial Comparing Efficacy and Safety of Initial Triple Therapy Including Parenteral Treprostinil to Initial Double Oral Therapy in Pulmonary Arterial Hypertension (PAH) Group I Patients (TripleTRE)
Lead sponsor
AOP Orphan Pharmaceuticals AG
Phase
Phase 4
Overall status
Recruiting
Start date
December 6, 2023
Completion date
June 30, 2027
Enrollment
110 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension